[go: up one dir, main page]

MX2019006670A - Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos. - Google Patents

Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos.

Info

Publication number
MX2019006670A
MX2019006670A MX2019006670A MX2019006670A MX2019006670A MX 2019006670 A MX2019006670 A MX 2019006670A MX 2019006670 A MX2019006670 A MX 2019006670A MX 2019006670 A MX2019006670 A MX 2019006670A MX 2019006670 A MX2019006670 A MX 2019006670A
Authority
MX
Mexico
Prior art keywords
methylphenidate
compositions
pharmaceutically acceptable
prodrugs
processes
Prior art date
Application number
MX2019006670A
Other languages
English (en)
Other versions
MX390156B (es
Inventor
Chi Guochen
Mickle Travis
M Guenther Sven
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of MX2019006670A publication Critical patent/MX2019006670A/es
Publication of MX390156B publication Critical patent/MX390156B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente tecnologia está dirigida composiciones que comprenden conjugados de d-treometilfenidato y metilfenidato no conjugado. La presente tecnología también se refiere a composiciones y formulaciones orales que comprenden d-treometilfenidato conjugado a nicotinoil-L-serina, y/o una sal farmacéuticamente aceptable del mismo, y metilfenidato no conjugado y/o una sal farmacéuticamente aceptable del mismo. La presente tecnología de manera adicional se refiere a un kit farmacéutico que contiene la composición que comprende d-treo-metilfenidato conjugado a nicotinoil-L-serina, y/o una sal farmacéuticamente aceptable del mismo, y metilfenidato no conjugado y/o una sal farmacéuticamente aceptable del mismo.
MX2019006670A 2016-12-11 2017-12-09 Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos MX390156B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662432675P 2016-12-11 2016-12-11
US201762519627P 2017-06-14 2017-06-14
US201762541695P 2017-08-05 2017-08-05
PCT/US2017/065482 WO2018107132A1 (en) 2016-12-11 2017-12-09 Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Publications (2)

Publication Number Publication Date
MX2019006670A true MX2019006670A (es) 2019-12-16
MX390156B MX390156B (es) 2025-03-20

Family

ID=62491385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006670A MX390156B (es) 2016-12-11 2017-12-09 Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos

Country Status (24)

Country Link
US (10) US10584112B2 (es)
EP (2) EP3551619B1 (es)
JP (1) JP6963614B2 (es)
KR (1) KR102337138B1 (es)
CN (1) CN110234636B (es)
AU (2) AU2017371327B2 (es)
BR (1) BR112019011640B1 (es)
CA (1) CA3046486A1 (es)
DK (1) DK3551619T3 (es)
ES (1) ES2979262T3 (es)
FI (1) FI3551619T3 (es)
HR (1) HRP20240748T1 (es)
HU (1) HUE067004T2 (es)
IL (3) IL322584A (es)
LT (1) LT3551619T (es)
MX (1) MX390156B (es)
NZ (1) NZ754751A (es)
PL (1) PL3551619T3 (es)
PT (1) PT3551619T (es)
RS (1) RS65591B1 (es)
SI (1) SI3551619T1 (es)
SM (1) SMT202400217T1 (es)
WO (1) WO2018107132A1 (es)
ZA (1) ZA201903928B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9653940B2 (en) 2015-06-02 2017-05-16 Voyetra Turtle Beach, Inc. Headset wireless charging dock
SMT202400217T1 (it) 2016-12-11 2024-07-09 Zevra Therapeutics Inc Composizioni comprendenti profarmaci di metilfenidato, processi per la loro produzione e uso
WO2019241020A1 (en) * 2018-06-15 2019-12-19 Kempharm, Inc. Serdexmethylphenidate conjugates, compositions and methods of use thereof
US11136295B2 (en) * 2018-10-29 2021-10-05 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same
IL295986A (en) * 2020-02-29 2022-10-01 Kempharm Inc Compositions comprising methylphenidate-prodrugs, processes of making and using the same
US11805352B2 (en) 2021-05-28 2023-10-31 Plantronics, Inc. Wireless charging dock
US20250375436A1 (en) 2024-03-25 2025-12-11 Zevra Therapeutics, Inc. Serdexmethylphenidate for treatment of idiopathic hypersomnia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
WO1999036403A1 (en) 1998-01-13 1999-07-22 The Trustees Of The University Of Pennsylvania Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20020132793A1 (en) 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
CA2420569A1 (en) 2000-08-28 2002-03-07 Mel H. Epstein Use of threo-methylphenidate compounds to enhance memory
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
IL151251A0 (en) 2002-08-14 2003-04-10 Elta Systems Ltd Parallel processing platform with synchronous system halt-resume
WO2004080959A2 (en) 2003-03-07 2004-09-23 Isp Investments Inc. Process for the preparation of dexmethylphenidate hydrochloride
DK1644019T4 (en) * 2003-05-29 2018-04-23 Shire Llc AMPHETAMINE COMPOUNDS RESISTANT TO ABUSE
WO2006047330A2 (en) 2004-10-22 2006-05-04 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2007022535A2 (en) 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
BRPI0715633A2 (pt) * 2006-08-23 2013-07-02 Univ Montana mÉtodo de reduÇço de dano em cÉlula neuronal
WO2008073918A1 (en) 2006-12-11 2008-06-19 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
WO2008097546A2 (en) 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP2109465B1 (en) 2007-02-08 2012-04-11 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
BRPI0808962A2 (pt) 2007-03-15 2014-08-26 Sun Pharma Advanced Res Co Ltd Agente para drogas
EP2152690B1 (en) 2007-05-23 2012-01-11 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
UA112654C2 (uk) 2011-07-28 2016-10-10 Кемфарм Інк. Проліки метилфенідату
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
US9088326B2 (en) 2012-07-18 2015-07-21 Rf Micro Devices, Inc. Front end radio architecture having a split band arrangement with co-banding
WO2018107131A1 (en) 2016-12-11 2018-06-14 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
SMT202400217T1 (it) * 2016-12-11 2024-07-09 Zevra Therapeutics Inc Composizioni comprendenti profarmaci di metilfenidato, processi per la loro produzione e uso
WO2019241020A1 (en) * 2018-06-15 2019-12-19 Kempharm, Inc. Serdexmethylphenidate conjugates, compositions and methods of use thereof

Also Published As

Publication number Publication date
US11021459B2 (en) 2021-06-01
AU2017371327B2 (en) 2020-10-15
DK3551619T3 (da) 2024-06-10
EP3551619B1 (en) 2024-03-06
FI3551619T3 (fi) 2024-05-30
US20200062731A1 (en) 2020-02-27
US20190282559A1 (en) 2019-09-19
PL3551619T3 (pl) 2024-07-22
NZ754751A (en) 2022-05-27
US11021460B2 (en) 2021-06-01
CA3046486A1 (en) 2018-06-14
JP2020502091A (ja) 2020-01-23
SI3551619T1 (sl) 2024-08-30
ES2979262T3 (es) 2024-09-25
WO2018107132A1 (en) 2018-06-14
HRP20240748T1 (hr) 2024-09-13
BR112019011640B1 (pt) 2021-08-17
HUE067004T2 (hu) 2024-10-28
ZA201903928B (en) 2023-03-29
CN110234636A (zh) 2019-09-13
BR112019011640A2 (pt) 2019-10-22
AU2017371327A1 (en) 2019-07-11
US20210253552A1 (en) 2021-08-19
US10954213B2 (en) 2021-03-23
AU2020239746B2 (en) 2021-07-08
LT3551619T (lt) 2024-06-25
US11505537B2 (en) 2022-11-22
US20190284166A1 (en) 2019-09-19
IL267172A (en) 2019-08-29
JP6963614B2 (ja) 2021-11-10
US20200181114A1 (en) 2020-06-11
AU2020239746A1 (en) 2020-10-22
EP3551619A1 (en) 2019-10-16
KR20190091461A (ko) 2019-08-06
RS65591B1 (sr) 2024-06-28
SMT202400217T1 (it) 2024-07-09
US20200016273A1 (en) 2020-01-16
US20200181113A1 (en) 2020-06-11
EP4364802A2 (en) 2024-05-08
US20200061198A1 (en) 2020-02-27
US10954212B2 (en) 2021-03-23
CN110234636B (zh) 2022-09-20
IL297652B2 (en) 2026-01-01
PT3551619T (pt) 2024-06-14
IL297652B1 (en) 2025-09-01
US10584112B2 (en) 2020-03-10
US10584113B2 (en) 2020-03-10
EP3551619A4 (en) 2020-07-22
IL322584A (en) 2025-10-01
US20210130322A1 (en) 2021-05-06
KR102337138B1 (ko) 2021-12-08
IL297652A (en) 2022-12-01
MX390156B (es) 2025-03-20
US10858341B2 (en) 2020-12-08
US10759778B2 (en) 2020-09-01
EP4364802A3 (en) 2024-07-03
US20200016272A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MX2019006670A (es) Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos.
HK1203309A1 (zh) 抗體-藥物綴合物以及相關化合物、組合物和方法
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
CY1116698T1 (el) Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
EA201070699A1 (ru) Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
MX384800B (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
TR201717703A2 (tr) Api̇ksaban formülasyonlari
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX393915B (es) Nuevas formulaciones orales de belinostat.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
WO2023009759A3 (en) Antibody-drug conjugates and methods of use thereof